Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
88 89 Next >
News headline image
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely. 
Via MarketBeat
Topics Economy
News headline image
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday? ↗
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
News headline image
2 Beaten-Down Stocks to Buy and Hold for 10 Years ↗
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
News headline image
Catalyst's New CEO Has Big Ideas For The Small Biotech ↗
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
News headline image
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields ↗
 
Via Benzinga
News headline image
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Bristol-Myers Squibb? ↗
 
Via Benzinga
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
News headline image
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields ↗
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
From Bristol Myers Squibb
Via Business Wire
News headline image
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback ↗
Investors should considered these discounted stocks to buy for generous returns due to current undervaluation and strong fundamentals. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire? ↗
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock. 
Via The Motley Fool
News headline image
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today ↗
The answer isn't great, but there's still reason to like Bristol Myers Squibb. 
Via The Motley Fool
News headline image
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 Top ETFs to Buy for Passive Income in May ↗
These ETFs provide investors with above-average income streams. 
Via The Motley Fool
Topics ETFs
News headline image
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024) ↗
10 worst performing large-cap stocks last week: LKQ, MSCI, TXT, EDU, BMY, MANH, RS, META, LUV, NUE. Analysts cut price targets for many. 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights ↗
 
Via Benzinga
News headline image
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
News headline image
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results ↗
 
Via Benzinga
News headline image
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions ↗
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for... 
Via Benzinga
News headline image
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal ↗
Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel. 
Via InvestorPlace
Topics Artificial Intelligence
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.